After multivariate adjustment, we observed that the PBL PBX3 hypermethylation in CRC patients was independently associated with a better 10‐year OS ([HRMultivariate‐adjusted]: 0.71 [95% CI, 0.51‐1.00; P = 0.049]), and marginally associated with a better DFS ([HRMultivariate‐adjusted]: 0.72 [95% CI, 0.51‐1.02; P = 0.06]). Here, PBX3 is linked to colorectal carcinoma.